Sitemap
- Commercial Solutions
- Industry Resources
- News
- Triangle Insights Group by Mercalis Announces Promotion of Parker Guse
- Policy Reporter by Mercalis and AccessSync Announce Strategic Partnership to Transform Market Access Capabilities
- PharmaCord and Mercalis to Merge, Creating Next-Generation Platform to Meet Evolving Needs of the Biopharmaceutical Industry
- September 10, 2024: Turquoise Health and Policy Reporter by Mercalis Announce Strategic Data Partnership
- Policy Reporter by Mercalis Introduces Payer Compliance Dashboard
- Mercalis Launches With An End-to-End Vision For Life Sciences Companies
- Blog: Mercalis at the Helm
- Biotech Funding in 2025: Navigating the New Investment Landscape
- Beyond the Fine Print: How Healthcare Systems Are Mastering Payer Claims Requirements to Prevent Revenue Leakage
- Drug Channels - Unlocking AI's Promise in Patient Support Programs
- Insights and Innovations from Informa's Recent Copay and Patient Support Congresses
- The Future of Cell and Gene Therapy Manufacturing
- The Changing Landscape of Specialty Pharma Reimbursement in 2024
- Leveraging Copay Data-driven Insights to Improve HCP Engagements
- Navigating Market Access Challenges in Life Sciences Commercialization
- Trust Matters: Healthcare Providers Changing Preferences in Pharma
- Podcast: Mercalis in Motion
- Optimizing HCP Engagement: Strategies for Every Stage of the Product Life Cycle
- Mercalis Executive Leadership Reflects on 2024 Successes and Future Strategy
- Lessons on Employee Engagement, Culture, and Inclusivity in the Post-Pandemic Workplace
- 2024 in Review: Noteworthy Guests and Key Discussions
- Biosimilars and their Impact on Pharma Patient Support Services
- Mercalis Celebrates 15 Years of RxStudy Card
- Simplifying eServices with Mercalis eServices Curator
- The Mercalis Nurse Network
- Market Trends, AI Strategy, and More: A Conversation With Policy Reporter by Mercalis
- Triangle Insights Group by Mercalis: A Discussion About the Inflation Reduction Act
- Mercalis Commemorates Rare Disease Day 2024
- A Conversation With Mercalis CEO Scott Dulitz
- 2023 in Review: Noteworthy Guests and Key Discussions
- Copay Accumulator Plan Designs: What Life Sciences Manufacturers Need to Know Heading into 2024
- TrialCard is Now Mercalis!
- Navigating Alternate Funding Programs
- Diversity, Equity, and Inclusion: A Conversation With Mercalis
- Mercalis' Nursing Team: A Difference Maker in Patient Services
- Triangle Insights Group by Mercalis
- Creating a More Efficient Clinical Supply Process with Mercalis's RxStudy Card
- Policy Reporter: Demystifying Payer Coverage To Serve Patients
- Best of 2022 – Mercalis Podcast
- Mercalis CEO Scott Dulitz
- A Conversation with Dean Erhardt, President & CEO of D2 Solutions
- Mercalis’ Non-Commercial Dispensing Pharmacy
- Videos
- Mercalis Expands Non-Commercial Dispensing Pharmacy
- Mercalis Patient Journey Demo: Account Management
- Mercalis Patient Journey Demo: Copay Support Program
- Mercalis Patient Journey Demo: Clinical Support
- Mercalis Patient Journey Demo: Field Reimbursement Support
- Mercalis Patient Journey Demo: Free Goods Program Support
- Mercalis Patient Journey Demo: eServices
- Mercalis Patient Journey Demo: Enrollment
- Mercalis Patient Journey Demo: Introduction
- Introducing the Mercalis Pharmacy
- Brochures
- Unlocking Market Access: Comparison of SCS & PNS for Pain Management
- How Policy Reporter Supports Specialty Associations With Comprehensive Payer Intelligence
- Unlocking Opportunities in Healthcare: Connecting with Healthcare Professionals Where it Matters Most
- Mercalis Healthcare Provider Engagement Strategies
- Cell and Gene Therapy Wrapped: 2023 Review
- RxStudy Card: Clinical Supplies Simplified
- White Papers
- Beyond Coding: Understanding Payer Publications Supporting the Revenue Cycle
- The Evolving Landscape of ctDNA Testing Payer Coverage
- Retrospective: 100 Years of Diabetes Management Evolution
- The Indirect Impacts of the Inflation Reduction Act on Pharmaceutical Pipeline and Portfolio Strategy
- Pharmaceutical Commercial Forecasting
- Optimizing Patient Services for Biosimilars: Strategies for a Market Access-Driven Landscape
- Biosimilars Commercialization: Lessons Learned from Adalimumab and Four Necessary Approaches
- Building a Better On-Ramp to Access Therapy: How Technology-first Solutions Provide Speed to Therapy and Cost Savings for Pharmaceutical Manufacturers.
- The 2024 Guide to Compliant Pharmaceutical Speaker Programs
- Navigating Market Access Challenges in Life Sciences Commercialization
- Specialty Carve-Out Programs: Are They Affecting Your Patient Affordability Program?
- Why the Medicare Specialty Threshold Shouldn’t Drive Pricing Strategy
- How Policy Reporter Supports Specialty Associations With Comprehensive Payer Intelligence
- The 2023 Partnering Performance and Reputation Survey Report
- Drug Provisions in the Inflation Reduction Act (IRA)
- Data-Driven LCM Contracting Strategy: A Case Study
- Betting on Hide and Seek with AAV
- Applying Stakeholder Understanding to Design Digital Health Commercial Models
- IDN Engagement Strategy: Why All Therapeutics Need One
- Should Enthusiasm Surrounding Antibiotics Be Tempered?
- Strategic Portfolio Prioritization in the Age of Gene and Cell Therapy
- The U.S. Biosimilar Market: Do Analysts Have It Wrong?
- Pharmaceutical Business Development Transactions Operations
- Pharmaceutical Commercial Forecasting: Distilling Insights from Primary Research
- Focusing on the Market Environment to Improve Pharmaceutical Revenue Forecasting
- Partnering Performance and Reputation Survey Report 2020
- Combination Therapy in Oncology
- An Early View on Nine Aspects of the Emerging Gene Editing Market
- Closer to the Mark: Focusing on the Market Environment to Improve Pharmaceutical Revenue Forecasting
- Immuno-Oncology: Breakthrough but Not Unbounded
- Insights Into the Market for Infliximab
- Out of Pocket Elasticity: New Situations Highlight the Importance of Understanding Patient Responses to Cost Burden Sharing
- Immunology to Oncology: A Study of Biosimilar Market Evolution
- Licensing Lifeline: One Strategy for Catching Up After the Quarantine Pause
- A Closer Look: Payer Treatment of Prescription Digital Behavior Therapy
- A Closer Look: Summary of Digital Therapeutics Applications for Diabetes Management
- Pharma Services Due Diligence: Identifying the Commercial Factors Impacting a Successful Private Equity Transaction
- Executive Summary: Payer Skepticism about Digital Therapeutics
- 100 Years of Diabetes Management Evolution
- Results-Driven Access to Healthcare Providers Throughout The Patient Journey
- A Closer Look: Prescription Digital Therapeutics - By the Numbers - Payer Survey
- Reaching Providers When an In-Person Interaction Isn’t Possible
- News
- News
- Triangle Insights Group by Mercalis Strengthens Team With Hiring of New Partner
- Mercalis Reports Strong Performance And Significant Milestones in Fiscal Year 2024
- Mercalis Announces Expansion of Non-Commercial Dispensing Pharmacy With State-of-the-Art Technology
- Turquoise Health and Policy Reporter by Mercalis Announce Strategic Data Partnership
- Policy Reporter by Mercalis Introduces Payer Compliance Dashboard
- Mercalis and Triangle Insights Group Announce Senior Leadership Appointments
- Meet Us at Asembia’s 20th Summit in Las Vegas
- Mercalis Releases 2023 Annual Highlights
- Mercalis Announces Expansion Of Access And Adherence Technologies
- Mercalis and Triangle Insights Group Announce Executive Leadership Appointments
- Trust Matters: Healthcare Providers Changing Preferences in Pharma Engagement
- Q&A with Scott Dulitz, CEO of Mercalis
- Mercalis Launches With An End-to-End Vision For Life Sciences Companies
- Mercalis (formerly TrialCard) Files Brief Supporting PhRMA Lawsuit Against CMS Final Rule on Manufacturer Coupons and Best Price
- Mercalis (formerly TrialCard) Releases 2022 Annual Highlights
- Mercalis (formerly TrialCard) Responds to FTC on Harmful Impact of Pharmacy Benefit Manager (PBM) Practices on Consumers
- Mercalis (formerly TrialCard) Names Scott Dulitz Chief Executive Officer
- U.S. District Court Strikes Down 2023 CMS Final Rule on Pharmaceutical Manufacturer Coupons and Best Price
- Solving the Copay and Best Price Challenge
- Mercalis (formerly TrialCard) Announces Acquisition of Triangle Insights Group
- 2021 Co-Pay Accumulator, Maximizer, and Best Price Insights
- Mercalis (formerly TrialCard) Releases 2021 Annual Highlights
- Mercalis (formerly TrialCard) Awarded Contract with US Department of Health and Human Services
- Mercalis (formerly TrialCard) Announces Strategic Partnership with ClientPharma
- Mercalis (formerly TrialCard) Named #2 Fastest Growing Privately Held Company in the Triangle
- Mercalis (formerly TrialCard) Announces Acquisition of Archer Healthcare
- Mercalis (formerly TrialCard) Named #5 Fastest Growing Privately Held Company in the Triangle
- Conducting Patient Access in an Evolving Market
- Mercalis (formerly TrialCard) Names Scott Dulitz President & Chief Strategy Officer
- Mercalis (formerly TrialCard) Selects Infinitus Systems to Automate Payer Contact Center Activity
- Mercalis (formerly TrialCard) Launches EngageHCP
- Predictive Payer Coverage Solutions: Enabling Clients to Hit the Ground Running
- TrialCard’s Sini Abraham Receives Triangle Business Journal’s 40 Under 40 Leadership Award
- TrialCard’s Inspiring Hope Campaign Exceeds Fundraising Goal
- A Framework to Optimize Patient Access and Drive Value in the Care Continuum
- Mercalis' (formerly TrialCard) Policy Reporter Announces Launch of Its Coverage Viewer—Pharmacy Edition
- Rare Disease: Stopping at Nothing
- No Rare Disease Patient Goes Forgotten
- TC Script to the Rescue
- TrialCard Reports Third Consecutive Year of Double-Digit Growth
- 2021 Outlook: Five Themes That Will Define Co-Pay Assistance
- CMS Releases Final Rule Impacting Co-Pay Assistance Programs and Best Price
- Mercalis (formerly TrialCard) Reports 42% Organic Growth and Acquires Three Companies in 2019
- Mercalis' (formerly TrialCard) Mango Health Announces New Interoperable Technology Platform
- New Payer Policies Introduce Co-Pay Accumulators to Medical Benefit Products: Implications for Manufacturer Programs
- TrialCard Announces Acquisition of Canary Insights
- TC Script: Navigating Supply Chain During COVID-19
- Clinical Supply: Time and Cost Savings
- Mercalis (formerly TrialCard) Submits Comments Opposing CMS Best Price Proposed Rule
- Massachusetts Study Highlights Co-Pay Assistance as Positively Impacting Patient Access & Adherence
- Co-Pay Programs: The CMS Best Price Revision
- Time Management in Clinical Trial Supplies
- The 2021 Notice of Benefit and Payment Parameters: The Impact on Co-Pay Programs
- Payer Intelligence: How Can It Be Combined With Technology to Enhance Patient Access?
- Health Plans Scramble To Publish New Policies On COVID-19 Testing, Diagnosis and Treatment
- Clinical Supply Availability & Speed to Study Start-Up
- COVID-19: A Message from President & CEO, Mark Bouck
- Rare is mighty. Rare is exceptional.
- Co-Pay Card Fraud Detection: The Role of Processes and People
- Pharmacy Fraud Within Pharmaceutical Co-Pay Programs: What You Need to Know
- Law and Order: Pharmacy Fraud Unit